-
Hansoh Pharmaceutical’s HS-10511 Tablets for Hypertrophic Cardiomyopathy Cleared for Clinical Trials
•
Hansoh Pharmaceutical (HKG: 3692) has announced that its affiliated company’s self-developed Class 1 new drug, HS-10511 tablets, have received approval for clinical trials from the National Drug Administration. The drug is intended for the treatment of hypertrophic cardiomyopathy, a condition that requires significant medical innovation. Clinical Trial Approval and IndicationThe…
-
Chiesi Farmaceutici and Shanghai Pharmaceutical Partner on Distribution at CIIE
•
Among the series of deals secured by multinational corporations at the 6th China International Import Expo (CIIE), Italy-based Chiesi Farmaceutici S.p.A. has inked a partnership with Shanghai Pharmaceuticals Co., Ltd (SHA: 601607, HKG: 2607). This strategic alliance aims to capitalize on Shanghai Pharmaceutical’s extensive distribution network. As reported by Shine,…
-
Bayer Shifts Focus of Recursion Pharmaceuticals Collaboration to Precision Oncology
•
Germany-headquartered Bayer (ETR: BAYN) has announced a significant modification to its 2020 drug discovery collaboration with US biotechnology firm Recursion Pharmaceuticals (NASDAQ: RXRX). The partnership, which was initially focused on fibrosis, will now shift its attention to precision oncology. This strategic move will see the initiation of up to seven…
-
Lizhu Pharmaceutical Cancels ChiNext IPO, Opts for NEEQ Listing for Subsidiary Lizhu Reagent
•
On November 11, 2023, Lizhu Pharmaceutical (HKG: 1513) announced a strategic shift in its plans for its subsidiary, Lizhu Reagent. The company has decided to terminate its initial plan to spin off Lizhu Reagent for a listing on the Shenzhen Stock Exchange’s ChiNext board. Instead, it will file for a…
-
Novo Nordisk Commits Over DKK 42 Billion to Expand Chronic Disease Production in Denmark
•
Novo Nordisk (CPH: NOVO-B), a leading pharmaceutical company, last week announced a substantial plan to invest over DKK 42 billion (USD 6.0 billion) into expanding its production capacity for serious chronic diseases in Denmark. This significant investment underscores the company’s commitment to addressing the growing needs of patients with chronic…
-
Eli Lilly China’s President Benjamin L. Basil to Depart for Personal Reasons
•
It has been reported that Benjamin L. Basil, the current president and general manager of Eli Lilly (NYSE: LLY) China, will be leaving his position and the country for personal reasons. This change comes after Basil assumed the role in September 2022, succeeding Julio Gay-Ger. Background and AchievementsBasil’s tenure at…
-
Clinical Research on rAAV Gene Drug ZS805 for Fabry Disease Launched by Zhishan Weixin
•
Zhishan Weixin Biotechnology Co., Ltd, a China-based biotech company, has announced the launch of the first clinical research project in China focused on a recombinant adeno-associated virus (rAAV) genetic therapy for the treatment of Fabry disease. The study will evaluate the adeno-associated virus vector ZS805 as a potential treatment across…
-
Jiangsu Hengrui Medicine’ Subsidiary Shengdi Pharmaceuticals Receives NMPA Approval for HRS-9057
•
Jiangsu Hengrui Medicine (SHA: 600276), a leading pharmaceutical company in China, has announced that its subsidiary, Shengdi Pharmaceuticals, has received clinical trial approval from the National Medical Product Administration (NMPA) for HRS-9057 tablets. This Class 1 innovative drug will be assessed in clinical trials as a potential treatment for autosomal…
